Inhibikase Therapeutics, Inc. (NYSE:IKT) Expected to Earn Q2 2024 Earnings of ($0.58) Per Share
Inhibikase Therapeutics, Inc. (NYSE:IKT – Free Report) – Equities researchers at HC Wainwright dropped their Q2 2024 EPS estimates for Inhibikase Therapeutics in a note issued to investors on Tuesday, May 21st. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($0.58) for the quarter, down from their […]
More Stories
Head to Head Analysis: U Power (NASDAQ:UCAR) & Dorman Products (NASDAQ:DORM)
U Power (NASDAQ:UCAR – Get Free Report) and Dorman Products (NASDAQ:DORM – Get Free Report) are both auto/tires/trucks companies, but...
Village Farms International, Inc. (TSE:VFF) Director Buys C$12,552.30 in Stock
Village Farms International, Inc. (TSE:VFF – Get Free Report) Director Stephen Ruffini bought 10,000 shares of the firm’s stock in...
Jaguar Mining Inc. (TSE:JAG) Senior Officer Sells C$11,280.00 in Stock
Jaguar Mining Inc. (TSE:JAG – Get Free Report) Senior Officer Jonathan Victor Hill sold 2,000 shares of the firm’s stock...
Able View Global Inc. (NASDAQ:ABLV) Sees Significant Decline in Short Interest
Able View Global Inc. (NASDAQ:ABLV – Get Free Report) saw a significant decline in short interest in the month of...
Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $33.67
enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has been assigned an average recommendation of “Buy” from the seven analysts...
Brokerages Set Rubrik, Inc. (NYSE:RBRK) PT at $44.69
Rubrik, Inc. (NYSE:RBRK – Get Free Report) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are...